Author: admin

“Atrial Fibrillation Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Atrial Fibrillation Market.

The Atrial Fibrillation Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Atrial Fibrillation Pipeline Report:

• Companies across the globe are diligently working toward developing novel Atrial Fibrillation treatment therapies with a considerable amount of success over the years.

• Atrial Fibrillation companies working in the treatment market are Thryv Therapeutics Inc., Vivasc Therapeutics, Verseon, HUYA Bioscience, Novartis, AbbVie, Bayer AG, InCarda Therapeutics, Inc., and others, are developing therapies for the Atrial Fibrillation treatment

• Emerging Atrial Fibrillation therapies in the different phases of clinical trials are- Research programme, CTP-Amio, VE 1902, HBI-3000, HSY 244, AGN-151607, Asundexian, Inrhythm, and others are expected to have a significant impact on the Atrial Fibrillation market in the coming years.

• In January 2025, The initial phase of the ADVANTAGE AF clinical trial successfully met its safety and efficacy endpoints for treating drug-resistant, symptomatic, persistent atrial fibrillation using the FARAPULSE™ Pulsed Field Ablation System. Additionally, a sub-analysis from the OPTION clinical trial demonstrated consistent safety and effectiveness of the WATCHMAN FLX™ Left Atrial Appendage Closure Device when used after cardiac ablation, whether performed simultaneously (concomitant) or separately (sequential).

Atrial Fibrillation Overview

Atrial Fibrillation (AF) is an irregular or trembling heartbeat that raises the risk of blood clots, stroke, heart failure, and other issues related to the heart. The two upper chambers of the heart, known as the atria, beat erratically and chaotically during atrial fibrillation, not in time with the lower chambers, known as the ventricles.

Get a Free Sample PDF Report to know more about Atrial Fibrillation Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/atrial-fibrillation-pipeline-insight

Emerging Atrial Fibrillation Drugs Under Different Phases of Clinical Development Include:

• Research programme: Thryv Therapeutics Inc.

• CTP-Amio: Vivasc Therapeutics

• VE 1902: Verseon

• HBI-3000: HUYA Bioscience

• HSY 244: Novartis

• AGN-151607: AbbVie

• Asundexian: Bayer AG

• Inrhythm: InCarda Therapeutics, Inc.

Atrial Fibrillation Route of Administration

Atrial Fibrillation pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Atrial Fibrillation Molecule Type

Atrial Fibrillation Products have been categorized under various Molecule types, such as

• Monoclonal antibody

• Small molecule

• Peptide

Atrial Fibrillation Pipeline Therapeutics Assessment

• Atrial Fibrillation Assessment by Product Type

• Atrial Fibrillation By Stage and Product Type

• Atrial Fibrillation Assessment by Route of Administration

• Atrial Fibrillation By Stage and Route of Administration

• Atrial Fibrillation Assessment by Molecule Type

• Atrial Fibrillation by Stage and Molecule Type

DelveInsight’s Atrial Fibrillation Report covers around 15+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Atrial Fibrillation product details are provided in the report. Download the Atrial Fibrillation pipeline report to learn more about the emerging Atrial Fibrillation therapies

Some of the key companies in the Atrial Fibrillation Therapeutics Market include:

Key companies developing therapies for Atrial Fibrillation are – Bayer, Johnson and Johnson, Bristol Myers-Squibb, Daiichi Sankyo, Pfizer, Anthos Therapeutics, Cadrenal Therapeutics, Boehringer Ingelheim, InCarda Therapeutics, and others.

Atrial Fibrillation Pipeline Analysis:

The Atrial Fibrillation pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Atrial Fibrillation with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Atrial Fibrillation Treatment.

• Atrial Fibrillation key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Atrial Fibrillation Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Atrial Fibrillation market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Atrial Fibrillation drugs and therapies

Atrial Fibrillation Pipeline Market Drivers

• Rising prevalence of Atrial fibrillation, increase in the Adoption of Advanced Technologies are some of the important factors that are fueling the Atrial Fibrillation Market.

Atrial Fibrillation Pipeline Market Barriers

• However, complications associated with the use of Atrial fibrillation drugs, lack of awareness regarding medical therapy in underdeveloped and developing regions and other factors are creating obstacles in the Atrial Fibrillation Market growth.

Scope of Atrial Fibrillation Pipeline Drug Insight

• Coverage: Global

• Key Atrial Fibrillation Companies: Thryv Therapeutics Inc., Vivasc Therapeutics, Verseon, HUYA Bioscience, Novartis, AbbVie, Bayer AG, InCarda Therapeutics, Inc., and others

• Key Atrial Fibrillation Therapies: Research programme, CTP-Amio, VE 1902, HBI-3000, HSY 244, AGN-151607, Asundexian, Inrhythm, and others

• Atrial Fibrillation Therapeutic Assessment: Atrial Fibrillation current marketed and Atrial Fibrillation emerging therapies

• Atrial Fibrillation Market Dynamics: Atrial Fibrillation market drivers and Atrial Fibrillation market barriers

Request for Sample PDF Report for Atrial Fibrillation Pipeline Assessment and clinical trials

Table of Contents

1. Atrial Fibrillation Report Introduction

2. Atrial Fibrillation Executive Summary

3. Atrial Fibrillation Overview

4. Atrial Fibrillation- Analytical Perspective In-depth Commercial Assessment

5. Atrial Fibrillation Pipeline Therapeutics

6. Atrial Fibrillation Late Stage Products (Phase II/III)

7. Atrial Fibrillation Mid Stage Products (Phase II)

8. Atrial Fibrillation Early Stage Products (Phase I)

9. Atrial Fibrillation Preclinical Stage Products

10. Atrial Fibrillation Therapeutics Assessment

11. Atrial Fibrillation Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Atrial Fibrillation Key Companies

14. Atrial Fibrillation Key Products

15. Atrial Fibrillation Unmet Needs

16 . Atrial Fibrillation Market Drivers and Barriers

17. Atrial Fibrillation Future Perspectives and Conclusion

18. Atrial Fibrillation Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Atrial Fibrillation Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Bayer, Johnson and Johnson, Bristol Myers-Squibb, Daiichi Sankyo, Pfizer

“Peripheral Neuropathic Pain Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Peripheral Neuropathic Pain Market.

The Peripheral Neuropathic Pain Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Peripheral Neuropathic Pain Pipeline Report:

• Companies across the globe are diligently working toward developing novel Peripheral Neuropathic Pain treatment therapies with a considerable amount of success over the years.

• Peripheral Neuropathic Pain companies working in the treatment market are Trevena, Afasci, Lexicon Pharmaceuticals, Haisco Pharmaceutical, Vertex Pharmaceuticals, AlzeCure Pharma, Yuhan Corporation, Shanghai SIMR Biotech, GlaxoSmithKline, Lexicon Pharma, Jemincare, Eli Lilly and Company, Haisco Pharmaceutical, Aptinyx, Daiichi Sankyo, and others, are developing therapies for the Peripheral Neuropathic Pain treatment

• Emerging Peripheral Neuropathic Pain therapies in the different phases of clinical trials are- TRV045, AFA-281, LX9211, HSK16149, VX-548, ACD440 Gel, YHD1119, SR419, GW856553, LX9211 (blinded), JMKX000623, LY3857210, HSK16149, NYX-2925, DS-5565, Suzetrigine, and others are expected to have a significant impact on the Peripheral Neuropathic Pain market in the coming years.

• In November 2024, Sangamo Therapeutics announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for ST-503, an experimental epigenetic therapy aimed at treating intractable pain caused by idiopathic small fiber neuropathy (iSFN)—a form of chronic neuropathic pain.

Peripheral Neuropathic Pain Overview

Peripheral Neuropathic Pain is a type of chronic pain caused by damage or dysfunction in the peripheral nerves, which are the nerves outside the brain and spinal cord. It often results from conditions like diabetes (diabetic neuropathy), shingles (postherpetic neuralgia), trauma, or infections. Symptoms include burning, tingling, numbness, shooting pain, or heightened sensitivity in the affected areas. This pain can significantly impact quality of life. Treatment typically involves pain-relief medications, nerve-targeting drugs like anticonvulsants or antidepressants, and sometimes nerve blocks or physical therapy.

Get a Free Sample PDF Report to know more about Peripheral Neuropathic Pain Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/peripheral-neuropathic-pain-pipeline-insight

Emerging Peripheral Neuropathic Pain Drugs Under Different Phases of Clinical Development Include:

• TRV045: Trevena

• AFA-281: Afasci

• LX9211: Lexicon Pharmaceuticals

• HSK16149: Haisco Pharmaceutical

• VX-548: Vertex Pharmaceuticals

• ACD440 Gel: AlzeCure Pharma

• YHD1119: Yuhan Corporation

• SR419: Shanghai SIMR Biotech

• GW856553: GlaxoSmithKline

• LX9211 (blinded): Lexicon Pharma

• JMKX000623: Jemincare

• LY3857210: Eli Lilly and Company

• HSK16149: Haisco Pharmaceutical

• NYX-2925: Aptinyx

• DS-5565: Daiichi Sankyo

• Suzetrigine: Vertex Pharmaceuticals

Peripheral Neuropathic Pain Route of Administration

Peripheral Neuropathic Pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Peripheral Neuropathic Pain Molecule Type

Peripheral Neuropathic Pain Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

Peripheral Neuropathic Pain Pipeline Therapeutics Assessment

• Peripheral Neuropathic Pain Assessment by Product Type

• Peripheral Neuropathic Pain By Stage and Product Type

• Peripheral Neuropathic Pain Assessment by Route of Administration

• Peripheral Neuropathic Pain By Stage and Route of Administration

• Peripheral Neuropathic Pain Assessment by Molecule Type

• Peripheral Neuropathic Pain by Stage and Molecule Type

DelveInsight’s Peripheral Neuropathic Pain Report covers around 12+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Peripheral Neuropathic Pain product details are provided in the report. Download the Peripheral Neuropathic Pain pipeline report to learn more about the emerging Peripheral Neuropathic Pain therapies

Some of the key companies in the Peripheral Neuropathic Pain Therapeutics Market include:

Key companies developing therapies for Peripheral Neuropathic Pain are – Eli Lilly, Teva Pharma, Pfizer, Novartis, Johnson & Johnson, GlaxoSmithKline, Medtronic, and others.

Peripheral Neuropathic Pain Pipeline Analysis:

The Peripheral Neuropathic Pain pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Peripheral Neuropathic Pain with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Peripheral Neuropathic Pain Treatment.

• Peripheral Neuropathic Pain key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Peripheral Neuropathic Pain Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Peripheral Neuropathic Pain market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Peripheral Neuropathic Pain drugs and therapies

Peripheral Neuropathic Pain Pipeline Market Drivers

• High Prevalence and Growing Patient Pool, Advancements in Drug Development, are some of the important factors that are fueling the Peripheral Neuropathic Pain Market.

Peripheral Neuropathic Pain Pipeline Market Barriers

• However, Limited Efficacy of Existing Treatments, High Treatment Costs and Access Challenges, and other factors are creating obstacles in the Peripheral Neuropathic Pain Market growth.

Scope of Peripheral Neuropathic Pain Pipeline Drug Insight

• Coverage: Global

• Key Peripheral Neuropathic Pain Companies: Trevena, Afasci, Lexicon Pharmaceuticals, Haisco Pharmaceutical, Vertex Pharmaceuticals, AlzeCure Pharma, Yuhan Corporation, Shanghai SIMR Biotech, GlaxoSmithKline, Lexicon Pharma, Jemincare, Eli Lilly and Company, Haisco Pharmaceutical, Aptinyx, Daiichi Sankyo, and others

• Key Peripheral Neuropathic Pain Therapies: TRV045, AFA-281, LX9211, HSK16149, VX-548, ACD440 Gel, YHD1119, SR419, GW856553, LX9211 (blinded), JMKX000623, LY3857210, HSK16149, NYX-2925, DS-5565, Suzetrigine, and others

• Peripheral Neuropathic Pain Therapeutic Assessment: Peripheral Neuropathic Pain current marketed and Peripheral Neuropathic Pain emerging therapies

• Peripheral Neuropathic Pain Market Dynamics: Peripheral Neuropathic Pain market drivers and Peripheral Neuropathic Pain market barriers

Request for Sample PDF Report for Peripheral Neuropathic Pain Pipeline Assessment and clinical trials

Table of Contents

1. Peripheral Neuropathic Pain Report Introduction

2. Peripheral Neuropathic Pain Executive Summary

3. Peripheral Neuropathic Pain Overview

4. Peripheral Neuropathic Pain- Analytical Perspective In-depth Commercial Assessment

5. Peripheral Neuropathic Pain Pipeline Therapeutics

6. Peripheral Neuropathic Pain Late Stage Products (Phase II/III)

7. Peripheral Neuropathic Pain Mid Stage Products (Phase II)

8. Peripheral Neuropathic Pain Early Stage Products (Phase I)

9. Peripheral Neuropathic Pain Preclinical Stage Products

10. Peripheral Neuropathic Pain Therapeutics Assessment

11. Peripheral Neuropathic Pain Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Peripheral Neuropathic Pain Key Companies

14. Peripheral Neuropathic Pain Key Products

15. Peripheral Neuropathic Pain Unmet Needs

16 . Peripheral Neuropathic Pain Market Drivers and Barriers

17. Peripheral Neuropathic Pain Future Perspectives and Conclusion

18. Peripheral Neuropathic Pain Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Peripheral Neuropathic Pain Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Trevena, Afasci, Lexicon Pharma, Haisco Pharma, Vertex Pharma

“Emphysema Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Emphysema Market.

The Emphysema Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Emphysema Pipeline Report:

• Companies across the globe are diligently working toward developing novel Emphysema treatment therapies with a considerable amount of success over the years.

• Emphysema companies working in the treatment market are Kamada, Ltd., Hoffmann-La Roche, Aeris Therapeutics, Grifols Therapeutics, Sanofi, Mesoblast, Inc., and others, are developing therapies for the Emphysema treatment

• Emerging Emphysema therapies in the different phases of clinical trials are- Kamada AAT for inhalation, RAR Gamma, BLVR System, Alpha-1 MP, SAR447537, Prochymal™, and others are expected to have a significant impact on the Emphysema market in the coming years.

• In May 2025, Apreo Health, a clinical-stage medical device company focused on developing an innovative, tissue-preserving treatment for severe emphysema, announced the presentation of six-month, first-in-human clinical data from its BREATHE 1&2 trials. The data were featured in a late-breaking abstract session at the American Thoracic Society (ATS) 2025 International Conference in San Francisco and concurrently published in the American Journal of Respiratory and Critical Care Medicine (AJRCCM).

• The BREATHE trials mark the first clinical assessment of Apreo’s BREATHE Airway Scaffold, a bronchoscopically delivered, self-expanding implant designed to reduce lung hyperinflation in emphysema patients by enabling the release of trapped air.

• In January 2025, Aer Therapeutics (Aer), a biopharmaceutical company dedicated to advancing inhaled treatments for mucus-related lung conditions, announced the dosing of the first patient in its Phase 2a proof-of-concept (POC) clinical trial of fexlamose (formerly AER-01) for the treatment of Chronic Obstructive Pulmonary Disease (COPD).

Emphysema Overview

Emphysema is a chronic lung condition that is part of Chronic Obstructive Pulmonary Disease (COPD). It occurs when the air sacs (alveoli) in the lungs become damaged and lose their elasticity, making it difficult to breathe out fully. This leads to shortness of breath, especially during physical activity. The primary cause is long-term exposure to cigarette smoke, though air pollution and occupational fumes can also contribute. Emphysema is progressive and has no cure, but treatments like inhalers, medications, pulmonary rehabilitation, and lifestyle changes can help manage symptoms and improve quality of life.

Get a Free Sample PDF Report to know more about Emphysema Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/emphysema-pipeline-insight

Emerging Emphysema Drugs Under Different Phases of Clinical Development Include:

• Kamada AAT for inhalation: Kamada, Ltd.

• RAR Gamma: Hoffmann-La Roche

• BLVR System: Aeris Therapeutics

• Alpha-1 MP: Grifols Therapeutics

• SAR447537: Sanofi

• Prochymal™: Mesoblast, Inc.

Emphysema Route of Administration

Emphysema pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Emphysema Molecule Type

Emphysema Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

Emphysema Pipeline Therapeutics Assessment

• Emphysema Assessment by Product Type

• Emphysema By Stage and Product Type

• Emphysema Assessment by Route of Administration

• Emphysema By Stage and Route of Administration

• Emphysema Assessment by Molecule Type

• Emphysema by Stage and Molecule Type

DelveInsight’s Emphysema Report covers around 12+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Emphysema product details are provided in the report. Download the Emphysema pipeline report to learn more about the emerging Emphysema therapies

Some of the key companies in the Emphysema Therapeutics Market include:

Key companies developing therapies for Emphysema are – AstraZeneca, GlaxoSmithKline, Pfizer, Teva Pharmaceuticals, Novartis, Viatris, Orion Corporation, Boehringer IngelheimAstraZeneca, Teva Pharmaceuticals, xPfizer, Boehringer Ingelheim, and others.

Emphysema Pipeline Analysis:

The Emphysema pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Emphysema with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Emphysema Treatment.

• Emphysema key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Emphysema Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Emphysema market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Emphysema drugs and therapies

Emphysema Pipeline Market Drivers

• Rising prevalence of COPD and emphysema, fueled by aging populations and smoking rates—over 16 million US adults have COPD, Advances in therapeutic tech, including inhaled biologics, endobronchial valves, and minimally invasive lung volume reduction procedures, Increased healthcare spending and government initiatives supporting respiratory disease diagnosis and treatment, are some of the important factors that are fueling the Emphysema Market.

Emphysema Pipeline Market Barriers

• However, High cost of advanced diagnostics and treatments, including surgical procedures and biologics, limiting access globally, Limited specialized care, with shortages of trained respiratory professionals in many regions, Side effects from existing therapies, like corticosteroids and bronchodilators, which reduce patient adherence, and other factors are creating obstacles in the Emphysema Market growth.

Scope of Emphysema Pipeline Drug Insight

• Coverage: Global

• Key Emphysema Companies: Kamada, Ltd., Hoffmann-La Roche, Aeris Therapeutics, Grifols Therapeutics, Sanofi, Mesoblast, Inc., and others

• Key Emphysema Therapies: Kamada AAT for inhalation, RAR Gamma, BLVR System, Alpha-1 MP, SAR447537, Prochymal™, and others

• Emphysema Therapeutic Assessment: Emphysema current marketed and Emphysema emerging therapies

• Emphysema Market Dynamics: Emphysema market drivers and Emphysema market barriers

Request for Sample PDF Report for Emphysema Pipeline Assessment and clinical trials

Table of Contents

1. Emphysema Report Introduction

2. Emphysema Executive Summary

3. Emphysema Overview

4. Emphysema- Analytical Perspective In-depth Commercial Assessment

5. Emphysema Pipeline Therapeutics

6. Emphysema Late Stage Products (Phase II/III)

7. Emphysema Mid Stage Products (Phase II)

8. Emphysema Early Stage Products (Phase I)

9. Emphysema Preclinical Stage Products

10. Emphysema Therapeutics Assessment

11. Emphysema Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Emphysema Key Companies

14. Emphysema Key Products

15. Emphysema Unmet Needs

16 . Emphysema Market Drivers and Barriers

17. Emphysema Future Perspectives and Conclusion

18. Emphysema Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Emphysema Pipeline 2025: MOA, ROA, and Clinical Trial Insights Explored by DelveInsight | Kamada, Ltd., Hoffmann-La Roche, Aeris Therapeutics, Grifols Therapeutics, Sanofi

“Status Epilepticus Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Status Epilepticus Market.

The Status Epilepticus Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Status Epilepticus Pipeline Report:

• Companies across the globe are diligently working toward developing novel Status Epilepticus treatment therapies with a considerable amount of success over the years.

• Status Epilepticus companies working in the treatment market are Marinus Pharmaceuticals, Pfizer, UCB Biopharma, Rafa Laboratories, Sage Therapeutics, and others, are developing therapies for the Status Epilepticus treatment

• Emerging Status Epilepticus therapies in the different phases of clinical trials are- Ganaxolone, Lorazepam, Staccato alprazolam, Seizalam, SAGE-547, and others are expected to have a significant impact on the Status Epilepticus market in the coming years.

• In October 2024, Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a company focused on developing novel therapies for seizure disorders, has shared new findings from its pivotal Phase 3 RAISE trial investigating intravenous (IV) ganaxolone for the treatment of refractory status epilepticus (RSE). The data were presented at the Neurocritical Care Society (NCS) Annual Meeting. Initial results, released in June 2024, indicated that the trial achieved one of its two co-primary endpoints.

Status Epilepticus Overview

Status Epilepticus is a medical emergency characterized by a seizure lasting more than 5 minutes or multiple seizures occurring close together without full recovery of consciousness between them. It can affect people with or without a history of epilepsy and may result from brain injury, infection, stroke, or abrupt medication withdrawal. If not treated promptly, it can lead to permanent brain damage, coma, or death. Immediate intervention with anti-seizure medications, often intravenously, is essential to stop the seizures and stabilize the patient.

Get a Free Sample PDF Report to know more about Status Epilepticus Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/status-epilepticus-pipeline-insight

Emerging Status Epilepticus Drugs Under Different Phases of Clinical Development Include:

• Ganaxolone: Marinus Pharmaceuticals

• Lorazepam: Pfizer

• Staccato alprazolam: UCB Biopharma

• Seizalam: Rafa Laboratories

• IV Ganaxolone active: Marinus Pharmaceuticals

• SAGE-547: Sage Therapeutics

Status Epilepticus Route of Administration

Status Epilepticus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Status Epilepticus Molecule Type

Status Epilepticus Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

Status Epilepticus Pipeline Therapeutics Assessment

• Status Epilepticus Assessment by Product Type

• Status Epilepticus By Stage and Product Type

• Status Epilepticus Assessment by Route of Administration

• Status Epilepticus By Stage and Route of Administration

• Status Epilepticus Assessment by Molecule Type

• Status Epilepticus by Stage and Molecule Type

DelveInsight’s Status Epilepticus Report covers around 5+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Status Epilepticus product details are provided in the report. Download the Status Epilepticus pipeline report to learn more about the emerging Status Epilepticus therapies

Some of the key companies in the Status Epilepticus Therapeutics Market include:

Key companies developing therapies for Status Epilepticus are – UCB Biopharma SRL, Pfizer, Marinus Pharmaceuticals, Sage Therapeutics, Shire, and others.

Status Epilepticus Pipeline Analysis:

The Status Epilepticus pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Status Epilepticus with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Status Epilepticus Treatment.

• Status Epilepticus key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Status Epilepticus Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Status Epilepticus market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Status Epilepticus drugs and therapies

Status Epilepticus Pipeline Market Drivers

• Rising epilepsy prevalence, Advancements in drug development, Improved diagnostics & regulatory support, Technological innovation, are some of the important factors that are fueling the Status Epilepticus Market.

Status Epilepticus Pipeline Market Barriers

• However, Limited awareness & access, Adverse effects & safety concerns, High cost & infrastructure needs, Regulatory complexity, and other factors are creating obstacles in the Status Epilepticus Market growth.

Scope of Status Epilepticus Pipeline Drug Insight

• Coverage: Global

• Key Status Epilepticus Companies: Marinus Pharmaceuticals, Pfizer, UCB Biopharma, Rafa Laboratories, Sage Therapeutics, and others

• Key Status Epilepticus Therapies: Ganaxolone, Lorazepam, Staccato alprazolam, Seizalam, SAGE-547, and others

• Status Epilepticus Therapeutic Assessment: Status Epilepticus current marketed and Status Epilepticus emerging therapies

• Status Epilepticus Market Dynamics: Status Epilepticus market drivers and Status Epilepticus market barriers

Request for Sample PDF Report for Status Epilepticus Pipeline Assessment and clinical trials

Table of Contents

1. Status Epilepticus Report Introduction

2. Status Epilepticus Executive Summary

3. Status Epilepticus Overview

4. Status Epilepticus- Analytical Perspective In-depth Commercial Assessment

5. Status Epilepticus Pipeline Therapeutics

6. Status Epilepticus Late Stage Products (Phase II/III)

7. Status Epilepticus Mid Stage Products (Phase II)

8. Status Epilepticus Early Stage Products (Phase I)

9. Status Epilepticus Preclinical Stage Products

10. Status Epilepticus Therapeutics Assessment

11. Status Epilepticus Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Status Epilepticus Key Companies

14. Status Epilepticus Key Products

15. Status Epilepticus Unmet Needs

16 . Status Epilepticus Market Drivers and Barriers

17. Status Epilepticus Future Perspectives and Conclusion

18. Status Epilepticus Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Status Epilepticus Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Marinus Pharmac, Pfizer, UCB Biopharma, Rafa Laboratories, Sage Therapeutics

“Follicular Lymphoma Market”

(Albany, USA) DelveInsight’s “Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast-2034” report offers an in-depth understanding of the Follicular Lymphoma, historical and forecasted epidemiology as well as the Follicular Lymphoma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The Follicular Lymphoma market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Follicular Lymphoma market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Follicular Lymphoma treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Follicular Lymphoma market.

To Know in detail about the Follicular Lymphoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Follicular Lymphoma Market Forecast

Key highlights of the Follicular Lymphoma Market Report:

• The Follicular Lymphoma market size was valued ~USD 1,082 million in 2024 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In February 2025, Regeneron Pharmaceuticals announced the resubmission of the Biologics License Application (BLA) for odronextamab in relapsed/refractory follicular lymphoma to the FDA. The company expects a decision from the FDA in the second half of 2025.
• In February 2025, Genmab A/S (Nasdaq: GMAB) announced that the Japan Ministry of Health, Labour, and Welfare has approved EPKINLY Registered (epcoritamab) for treating patients with relapsed or refractory follicular lymphoma (FL; Grades 1 to 3A) who have undergone two or more prior treatments. This approval makes EPKINLY the first and only subcutaneously administered T-cell engaging bispecific antibody approved in Japan for both relapsed or refractory FL and large B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, and primary mediastinal large B-cell lymphoma, after two or more prior therapies.
• In January 2025, CRISPR Therapeutics announced plans to collaborate with regulatory authorities to determine the next steps for CTX112 in B-cell malignancies, with an update anticipated by mid-2025.
• In September 2024, The FDA granted Priority Review status to the Biologics License Application (BLA) for odronextamab, intended for the treatment of adults with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma (DLBCL) who have not responded to at least two prior systemic therapies.
• In 2024, approximately 35,000 cases of follicular lymphoma were diagnosed across the 7MM.
• In 2024, the United States generated around USD 1,082 million in revenue.
• In 2024, Germany represented the largest market size among the EU4 and the UK, with an estimated value of around USD 108 million.
• In 2024, Spain had the smallest market size among the EU4 and the UK, with an estimated value of around USD 61 million.
• In 2024, the United States had the highest number of Follicular Lymphoma cases among the 7MM, with approximately 17,000 cases. This number is expected to rise by 2034.
• In 2024, the 60-80 age group had the highest incidence of follicular lymphoma, with around 9,000 cases, followed by the 40-59 age group with approximately 4,000 cases.
• In 2024, stage IV follicular lymphoma cases accounted for approximately 34% of all cases.
• In 2024, the incidence of follicular lymphoma in the EU4 and the UK was approximately 14,000, with Germany reporting the highest number of cases.
• Key Follicular Lymphoma Companies: Roche, BeiGene, Kite Pharma, Incyte Corporation, AstraZeneca, Xynomic Pharmaceuticals, MEI Pharma, Novartis, Innovent Biologics, Regeneron, Genentech, Xynomic Pharma, Eli Lilly and Company, ADC Therapeutics S.A, BeiGene, Cephalon, Epizyme, Inc., Pharmacyclics LLC., Gemin X, AbbVie, Millennium Pharma, and others
• Key Follicular Lymphoma Therapies: LUNSUMIO (mosunetuzumab), BRUKINSA (zanubrutinib), YESCARTA, MONJUVI (tafasitamab), AZD0486, Abexinostat, ME-401, Tisagenlecleucel, Parsaclisib (IBI376), Odronextamab, Mosunetuzumab, Abexinostat, Rituximab IV, Atezolizumab (MPDL3280A) [TECENTRIQ], Enzastaurin, Loncastuximab tesirine, Zanubrutinib, Bendamustine, Tazemetostat, ibrutinib, Obatoclax mesylate, Ibrutinib, IXAZOMIB, and others
• The Follicular Lymphoma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Follicular Lymphoma pipeline products will significantly revolutionize the Follicular Lymphoma market dynamics.

Follicular Lymphoma Overview

Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma that arises from B-lymphocytes, a type of white blood cell essential for the immune system. Follicular Lymphoma typically originates in the lymph nodes but can also affect the bone marrow and spleen. This form of lymphoma is characterized by the formation of abnormal follicles within lymph nodes, leading to painless swelling, fatigue, night sweats, and unexplained weight loss.

Follicular Lymphoma most commonly affects adults over the age of 60 and is usually diagnosed through a combination of physical examination, blood tests, imaging studies, and biopsy. Genetic testing may also be used to identify specific mutations, such as the BCL2 gene rearrangement, which is often associated with this disease.

Follicular Lymphoma treatment options vary depending on the stage and symptoms, ranging from active surveillance in early stages to targeted therapies, immunotherapy, chemotherapy, and radiation therapy in more advanced or symptomatic cases. While Follicular Lymphoma is generally considered incurable, it is highly treatable, and many patients live for years with proper disease management.

Follicular Lymphoma research continues to advance, with clinical trials exploring novel therapies aimed at improving outcomes and extending progression-free survival, making the future more hopeful for affected patients.

Get a Free sample for the Follicular Lymphoma Market Report: Follicular Lymphoma Treatment Market

Follicular Lymphoma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Follicular Lymphoma Epidemiology Segmentation:

The Follicular Lymphoma market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

• Total Prevalence of Follicular Lymphoma
• Prevalent Cases of Follicular Lymphoma by severity
• Gender-specific Prevalence of Follicular Lymphoma
• Diagnosed Cases of Episodic and Chronic Follicular Lymphoma

Download the report to understand which factors are driving Follicular Lymphoma epidemiology trends @ Follicular Lymphoma Epidemiology Forecast

Follicular Lymphoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Follicular Lymphoma market or expected to get launched during the study period. The analysis covers Follicular Lymphoma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Follicular Lymphoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Follicular Lymphoma Therapies and Key Companies

• LUNSUMIO (mosunetuzumab): Roche
• BRUKINSA (zanubrutinib): BeiGene
• YESCARTA: Kite Pharma
• MONJUVI (tafasitamab): Incyte Corporation
• AZD0486: AstraZeneca
• Abexinostat: Xynomic Pharmaceuticals
• ME-401: MEI Pharma
• Tisagenlecleucel: Novartis
• Parsaclisib (IBI376): Innovent Biologics
• Odronextamab: Regeneron
• Mosunetuzumab: Genetech
• Abexinostat: Xynomic Pharma
• Rituximab IV: Roche
• Atezolizumab (MPDL3280A) [TECENTRIQ]: Hoffmann-La Roche
• Enzastaurin: Eli Lilly and Company
• Loncastuximab tesirine: ADC Therapeutics S.A
• Zanubrutinib: BeiGene
• Bendamustine: Cephalon
• Tazemetostat: Epizyme, Inc.
• ibrutinib: Pharmacyclics LLC.
• Obatoclax mesylate: Gemin X
• Ibrutinib: AbbVie
• IXAZOMIB: Millennium Pharma

To know more about Follicular Lymphoma companies working in the treatment market, visit @ Follicular Lymphoma Medication, Manufacturers and Therapeutic Assessment

Follicular Lymphoma Market Outlook

DelveInsight estimates that the US market size for follicular lymphoma is expected to grow from USD 1 billion in 2024 at a significant CAGR by 2034. The follicular lymphoma market is experiencing steady growth, driven by rising incidence rates, increasing awareness, and advancements in targeted therapies such as monoclonal antibodies and CAR-T cell treatments. The aging global population further contributes to market expansion. Additionally, ongoing clinical trials and approvals of novel agents are expected to boost market opportunities in the coming years.

The anticipated launch of these emerging therapies for follicular lymphoma are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the follicular lymphoma market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

Scope of the Follicular Lymphoma Market Report

• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Follicular Lymphoma Companies: AbbVie (NYSE: ABBV), Genentech (subsidiary of Roche), Xynomic Pharma (OTC: XYNM), Regeneron (NASDAQ: REGN), Epizyme, Inc. (formerly NASDAQ: EPZM), ADC Therapeutics S.A (NYSE: ADCT), Kite Pharma (subsidiary of Gilead Sciences), Eli Lilly and Company (NYSE: LLY), Cephalon (acquired by Teva), Innovent Biologics (HKEX: 1801), Incyte Corporation (NASDAQ: INCY), Novartis (SWX: NOVN), MEI Pharma (NASDAQ: MEIP), AstraZeneca (LSE: AZN), BeiGene (NASDAQ: BGNE; HKEX: 6160), Millennium Pharma (subsidiary of Takeda), Roche (SWX: ROG), Gemin X (acquired by Cephalon), Pharmacyclics LLC. (formerly NASDAQ: PCYC), Xynomic Pharmaceuticals (OTC: XYNM), and others.
• Key Follicular Lymphoma Therapies: LUNSUMIO (mosunetuzumab), BRUKINSA (zanubrutinib), YESCARTA, MONJUVI (tafasitamab), AZD0486, Abexinostat, ME-401, Tisagenlecleucel, Parsaclisib (IBI376), Odronextamab, Mosunetuzumab, Abexinostat, Rituximab IV, Atezolizumab (MPDL3280A) [TECENTRIQ], Enzastaurin, Loncastuximab tesirine, Zanubrutinib, Bendamustine, Tazemetostat, ibrutinib, Obatoclax mesylate, Ibrutinib, IXAZOMIB, and others
• Follicular Lymphoma Therapeutic Assessment: Follicular Lymphoma current marketed and Follicular Lymphoma emerging therapies
• Follicular Lymphoma Market Dynamics: Follicular Lymphoma market drivers and Follicular Lymphoma market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Follicular Lymphoma Unmet Needs, KOL’s views, Analyst’s views, Follicular Lymphoma Market Access and Reimbursement

Discover more about therapies set to grab major Follicular Lymphoma drug market share @ Follicular Lymphoma Clinical Trials and FDA Approvals

Table of Contents

1. Follicular Lymphoma Market Report Introduction

2. Executive Summary for Follicular Lymphoma

3. SWOT analysis of Follicular Lymphoma

4. Follicular Lymphoma Patient Share (%) Overview at a Glance

5. Follicular Lymphoma Market Overview at a Glance

6. Follicular Lymphoma Disease Background and Overview

7. Follicular Lymphoma Epidemiology and Patient Population

8. Country-Specific Patient Population of Follicular Lymphoma

9. Follicular Lymphoma Current Treatment and Medical Practices

10. Follicular Lymphoma Unmet Needs

11. Follicular Lymphoma Emerging Therapies

12. Follicular Lymphoma Market Outlook

13. Country-Wise Follicular Lymphoma Market Analysis (2020-2034)

14. Follicular Lymphoma Market Access and Reimbursement of Therapies

15. Follicular Lymphoma Market Drivers

16. Follicular Lymphoma Market Barriers

17. Follicular Lymphoma Appendix

18. Follicular Lymphoma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Follicular Lymphoma Market Forecast 2034: EMA, PDMA, FDA Approval, Clinical Trials, Medication, Revenue, Statistics, Prevalence and Companies by DelveInsight